GlassScriptPhysician profile
Mitchell J Galerkin
NPI 1467440339
$23,383.61
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $2,618 · 2021: $1,078 · 2022: $98.20.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $14,351.97 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $6,864.69 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $444.06 | 2019-2022 | |
| Abbvie INC. | $338.43 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.93 | 2020-2022 | |
| Allergan, INC. | $175.33 | 2019-2020 | |
| Lundbeck LLC | $160.78 | 2019-2021 | |
| Neuronetics, INC. | $156.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $131.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.34 | 2019 | |
| Alfasigma USA, INC. | $73.43 | 2021 | |
| Shire North American Group INC | $67.67 | 2019 | |
| Vanda Pharmaceuticals INC. | $63.23 | 2019 | |
| Bausch Health US, LLC | $56.55 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $53.04 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $26.55 | 2019 | |
| Almatica Pharma LLC | $22.38 | 2021 | |
| Alkermes, INC. | $22.31 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.28 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Galerkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.